No registrations found.
ID
Source
Brief title
Health condition
Type 2 diabetes, cancer, kanker.
Sponsors and support
Intervention
Outcome measures
Primary outcome
Within-sulfonylurea-class differences in obesity-related cancer risk (hazard ratio).
Secondary outcome
Within-sulfonylurea-class differences in all cancer risk and site specific cancer risk of breast, colorectal, bladder, advanced prostate cancer and lung cancer, expressed as hazard ratio.
Study objective
Patients with Type 2 diabetes have been shown to have an increased risk for developing cancer, especially obesity related cancers. There is some evidence that within the class of sulfonylureas there is a difference in cancer risk; gliclazide could be associated with a decreased cancer risk when compared to the other sulfonylureas.
Study design
Hazard ratio will be calculated for a period up to 10 years.
Intervention
Individual sulfonylurea treatment (gliclazide, glimepiride, tolbutamide, glibenclamide)
Dennis Schrijnders
Zwolle 8025 BT
The Netherlands
0031-38-4247763
d.schrijnders@isala.nl
Dennis Schrijnders
Zwolle 8025 BT
The Netherlands
0031-38-4247763
d.schrijnders@isala.nl
Inclusion criteria
Type 2 diabetes patients treated with sulfonylureas
Exclusion criteria
Type 2 diabtes patientes treated with long-acting or mixed insulin before oral glucose lowering agents and those receiving insulin on top of sulfonylurea at study entry.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL6035 |
| NTR-old | NTR6166 |
| Other | : ZODIAC-55, METC 13.0765 |